drugset / Trial / NCT04528277

Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis

NCT04528277

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of the 1-month regimen of three times weekly rifapentine plus isoniazid in improving fertility outcome in recurrent implantation failure (RIF) patients with latent genital tuberculosis (LGTB), compared to no treatment and non-LGTB patients.

Timeline

Start
2020-09-01
Primary completion
2021-09-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Isoniazid Small molecule 400 mg Oral
Subject Rifapentine Small molecule 450 mg Oral